SURTELIUM Trademark

Trademark Overview

On Monday, November 28, 2011, a trademark application was filed for SURTELIUM with the United States Patent and Trademark Office. The USPTO has given the SURTELIUM trademark a serial number of 85481889. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, January 22, 2021. This trademark is owned by BIOFARMA. The SURTELIUM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for prevention and treatment of cardio-vascular diseases; anti-athero thrombotic pharmaceutical preparations
surtelium

General Information

Serial Number85481889
Word MarkSURTELIUM
Filing DateMonday, November 28, 2011
Status710 - CANCELLED - SECTION 8
Status DateFriday, January 22, 2021
Registration Number4549899
Registration DateTuesday, June 17, 2014
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 23, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparations for prevention and treatment of cardio-vascular diseases; anti-athero thrombotic pharmaceutical preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, January 22, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBIOFARMA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSuresnes cedex 92284
FR
Party NameBIOFARMA
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSuresnes cedex 92284
FR
Party NameBIOFARMA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSuresnes cedex 92284
FR

Trademark Events

Event DateEvent Description
Friday, January 22, 2021CANCELLED SEC. 8 (6-YR)
Monday, June 17, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, June 17, 2014REGISTERED-PRINCIPAL REGISTER
Wednesday, May 14, 20141(B) BASIS DELETED; PROCEED TO REGISTRATION
Wednesday, December 11, 2013NOTICE OF ALLOWANCE CANCELLED
Wednesday, December 11, 2013TEAS DELETE 1(B) BASIS RECEIVED
Thursday, February 6, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 5, 2014EXTENSION 2 GRANTED
Wednesday, December 18, 2013EXTENSION 2 FILED
Friday, January 31, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 18, 2013TEAS EXTENSION RECEIVED
Friday, June 7, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 5, 2013EXTENSION 1 GRANTED
Wednesday, June 5, 2013EXTENSION 1 FILED
Wednesday, June 5, 2013TEAS EXTENSION RECEIVED
Tuesday, December 18, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 23, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 23, 2012PUBLISHED FOR OPPOSITION
Wednesday, October 3, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, September 14, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, September 14, 2012ASSIGNED TO LIE
Thursday, September 6, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 4, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 3, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 3, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 21, 2012TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 15, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 15, 2012NON-FINAL ACTION E-MAILED
Thursday, March 15, 2012NON-FINAL ACTION WRITTEN
Saturday, March 10, 2012ASSIGNED TO EXAMINER
Friday, December 2, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, December 1, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

surtelium pharmaceutical preparations anti thrombotic diseases athero cardio prevention treatment vascular